Step Therapy Criteria
Customize your policy alerts
Sign up for all Independent Health policy alerts
Know when Independent Health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines step therapy requirements for drugs on the listed Independent Health/Pharmacy Benefit Dimensions formularies; affects prescribers and pharmacy prior authorization for members enrolled in the specified PDP Part D formulary.
No material clinical or coverage changes in this revision.
Step Therapy Coverage Criteria
Aliskiren Step Therapy
Covered when ALL of the following are met
Aripiprazole Formulation Sequencing
Covered when ALL of the following are met
Sequencing across formulations
EUCRISA Step Therapy
Covered when ALL of the following are met
Either agent satisfies step
Febuxostat Step Therapy
Covered when ALL of the following are met
SYMPAZAN Step Therapy
Covered when ALL of the following are met
TRELSTAR Step Therapy
Covered when ALL of the following are met
VERSACLOZ Step Therapy
Covered when ALL of the following are met
Doxercalciferol Step Therapy
Covered when ALL of the following are met
Required Prior Therapies (Sequencing)
| Coverage Label | Step requirement |
|---|---|
| Aliskiren fumarate 300 mg | |
| Try an angiotensin-II receptor blocker (ARB) before aliskiren fumarate 300 mg |
| Coverage Label | Step requirement |
|---|---|
| Aripiprazole oral solution -> ODT -> oral films | |
| Aripiprazole oral solution must be used before aripiprazole ODT; aripiprazole ODT must be used before aripiprazole oral films |
| Coverage Label | Step requirement |
|---|---|
| EUCRISA (crisaborole) ointment | |
| Prior use of either a topical corticosteroid OR a topical calcineurin inhibitor is required before EUCRISA ointment |
| Coverage Label | Step requirement |
|---|---|
| Febuxostat 80 mg | |
| Try allopurinol before febuxostat 80 mg |
| Coverage Label | Step requirement |
|---|---|
| SYMPAZAN films | |
| Try clobazam oral suspension before SYMPAZAN films |
| Coverage Label | Step requirement |
|---|---|
| TRELSTAR injectable formulations | |
| Try Lupron Depot before TRELSTAR injectable formulations |
| Coverage Label | Step requirement |
|---|---|
| VERSACLOZ suspension | |
| Try clozapine ODT before VERSACLOZ suspension |
| Coverage Label | Step requirement |
|---|---|
| Doxercalciferol capsules | |
| Try calcitriol before doxercalciferol capsules |
Prior Authorization and Provider Guidance
Step therapy prior‑authorization requirement
Prior authorization requires documentation of failure or trial of the specified first-line agent(s) listed for each product before covering the requested product.
Try an ARB before aliskiren 300 mg
Aliskiren fumarate 300 mg is subject to step therapy and requires prior use of an angiotensin‑II receptor blocker (ARB) before coverage.
Aripiprazole formulation sequencing
Sequencing across aripiprazole formulations is required: aripiprazole oral solution must be used before the orally‑disintegrating tablet (ODT), and the ODT must be used before aripiprazole oral films.
- Aripiprazole oral solution → Aripiprazole ODT
- Aripiprazole ODT → Aripiprazole oral films
Topical corticosteroid or calcineurin inhibitor required first
EUCRISA (crisaborole) ointment requires prior use of either a topical corticosteroid or a topical calcineurin inhibitor before coverage.
- Either a topical corticosteroid OR a topical calcineurin inhibitor satisfies the step
Try allopurinol before febuxostat 80 mg
Febuxostat 80 mg requires prior use of allopurinol before febuxostat will be covered.
Clobazam oral suspension required before SYMPAZAN films
SYMPAZAN films require prior use of clobazam oral suspension before coverage of the film formulation.
Try Lupron Depot before TRELSTAR injections
TRELSTAR injectable formulations require prior use of Lupron Depot before coverage of TRELSTAR injections.
Clozapine ODT required before VERSACLOZ suspension
VERSACLOZ oral suspension requires prior use of clozapine orally‑disintegrating tablet (ODT) before coverage.
Try calcitriol before doxercalciferol capsules
Doxercalciferol capsules require prior use of calcitriol before coverage will be provided.
Denial risk if ARB not tried before aliskiren 300 mg
Coverage may be denied if the required prior step (an angiotensin‑II receptor blocker) is not tried before aliskiren fumarate 300 mg.
Enforce aripiprazole formulation sequence
Aripiprazole oral solution must be tried before aripiprazole ODT, and aripiprazole ODT must be used before aripiprazole oral films; failure to follow sequencing may affect coverage.
- Solution → ODT → Oral films
EUCRISA requires prior topical steroid or calcineurin inhibitor
Topical corticosteroid or topical calcineurin inhibitor must be used before EUCRISA (crisaborole) ointment; lack of prior use may lead to noncoverage.
Denial risk if allopurinol not tried before febuxostat 80 mg
Allopurinol must be tried before febuxostat 80 mg; coverage for febuxostat 80 mg is contingent on prior allopurinol use.
SYMPAZAN requires prior clobazam suspension
Clobazam oral suspension must be used before SYMPAZAN films; failure to try the suspension first may prevent coverage of the film.
TRELSTAR coverage contingent on prior Lupron Depot
Lupron Depot must be used before TRELSTAR injectable formulations; absence of prior Lupron Depot use may result in denial.
VERSACLOZ requires prior clozapine ODT
Clozapine ODT must be used before VERSACLOZ oral suspension; coverage depends on prior use of the ODT formulation.
Doxercalciferol coverage requires prior calcitriol
Calcitriol must be used before doxercalciferol capsules; lack of prior calcitriol therapy may lead to noncoverage.
Member services and formulary notice
For questions about formulary rules or coverage, contact Medicare Member Services at 1-800-667-5936 (TTY 711). The formulary may change and members will be notified.
Listed Products and Codes
| aliskiren fumarate tablet 150 mg oral | listed in index |
| aliskiren fumarate tablet 300 mg oral | listed in index / step rule |
| aripiprazole tablet dispersible 10 mg oral | ODT listed |
| aripiprazole tablet dispersible 15 mg oral | ODT listed |
| doxercalciferol capsule 0.5 mcg oral | listed in index |
| doxercalciferol capsule 1 mcg oral | listed in index |
| doxercalciferol capsule 2.5 mcg oral | listed in index |
| EUCRISA OINTMENT 2 % EXTERNAL | listed |
| febuxostat tablet 40 mg oral | listed |
| febuxostat tablet 80 mg oral | listed / step rule |
Policy Background
This document lists the Step Therapy protocols used by the PDP Part D formulary to manage drug utilization and coverage. It is current as of May 1, 2026 and applies to the 2026 Pharmacy Benefit Dimensions Prescription Drug Plan (PDP) Part D 5‑Tier Formulary. The intent of these protocols is to require a trial and documented failure or intolerance of specified first‑line agent(s) before the formulary will cover alternative agents.
Providers and pharmacies should follow the listed sequencing rules when submitting prior authorization requests; for questions about coverage or the formulary, contact Medicare Member Services at the phone numbers and hours shown in the formulary notice. The formulary may change and members will be notified of necessary updates.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.